| PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin … P Borchmann, H Goergen, C Kobe, A Lohri, R Greil, DA Eichenauer, ... The Lancet 390 (10114), 2790-2802, 2017 | 379 | 2017 |
| Positron emission tomography–guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German … M Fuchs, H Goergen, C Kobe, G Kuhnert, A Lohri, R Greil, S Sasse, ... Journal of clinical oncology 37 (31), 2835-2845, 2019 | 208 | 2019 |
| Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma S Theurich, SI Rothschild, M Hoffmann, M Fabri, A Sommer, ... Cancer immunology research 4 (9), 744-754, 2016 | 156 | 2016 |
| Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial PJ Bröckelmann, H Goergen, U Keller, J Meissner, R Ordemann, ... JAMA oncology 6 (6), 872-880, 2020 | 151 | 2020 |
| PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial P Borchmann, A Plütschow, C Kobe, R Greil, J Meissner, MS Topp, ... The Lancet Oncology 22 (2), 223-234, 2021 | 137 | 2021 |
| Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab … P Borchmann, H Haverkamp, A Lohri, U Mey, S Kreissl, R Greil, ... The Lancet Oncology 18 (4), 454-463, 2017 | 93 | 2017 |
| Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma J Mettler, H Müller, CA Voltin, C Baues, B Klaeser, A Moccia, ... Journal of Nuclear Medicine 60 (2), 207-211, 2019 | 87 | 2019 |
| The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer MA Hoffmann, HJ Wieler, C Baues, NJ Kuntz, I Richardsen, ... Urology 130, 1-12, 2019 | 76 | 2019 |
| Abscopal effects in radio-immunotherapy—Response analysis of metastatic cancer patients with progressive disease under anti-PD-1 immune checkpoint inhibition M Trommer, SY Yeo, T Persigehl, A Bunck, H Gruell, M Schlaak, ... Frontiers in Pharmacology 10, 511, 2019 | 74 | 2019 |
| Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18 CA Voltin, H Goergen, C Baues, M Fuchs, J Mettler, S Kreissl, J Oertl, ... Annals of Oncology 29 (9), 1926-1931, 2018 | 56 | 2018 |
| Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group DA Eichenauer, A Plütschow, M Fuchs, S Sasse, C Baues, B Böll, ... Journal of Clinical Oncology 38 (7), 698-705, 2020 | 52 | 2020 |
| Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials B von Tresckow, S Kreissl, H Goergen, PJ Bröckelmann, T Pabst, ... The Lancet Haematology 5 (10), e462-e473, 2018 | 52 | 2018 |
| FDG-PET Imaging for Hodgkin and Diffuse large B-cell lymphoma—An updated overview CA Voltin, J Mettler, J Grosse, M Dietlein, C Baues, C Schmitz, ... Cancers 12 (3), 601, 2020 | 47 | 2020 |
| Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL … PJ Bröckelmann, I Bühnen, J Meissner, K Trautmann-Grill, P Herhaus, ... Journal of Clinical Oncology 41 (6), 1193-1199, 2023 | 42 | 2023 |
| Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma C Kobe, H Goergen, C Baues, G Kuhnert, CA Voltin, J Zijlstra, O Hoekstra, ... Blood, The Journal of the American Society of Hematology 132 (21), 2273-2279, 2018 | 41 | 2018 |
| PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial S Kreissl, H Goergen, I Buehnen, C Kobe, A Moccia, R Greil, ... The Lancet Haematology 8 (6), e398-e409, 2021 | 40 | 2021 |
| Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation: A Planning Comparison Of Deep Inspiration Breath Hold Intensity Modulation Radiotherapy A … C Baues, S Marnitz, A Engert, W Baus, K Jablonska, A Fogliata, ... Radiation Oncology 13, 1-11, 2018 | 40 | 2018 |
| Robotic stereotactic radiosurgery in melanoma patients with brain metastases under simultaneous anti-PD-1 treatment M Trommer-Nestler, S Marnitz, M Kocher, D Rueß, M Schlaak, S Theurich, ... International Journal of Molecular Sciences 19 (9), 2653, 2018 | 39 | 2018 |
| Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer L Käsmann, M Niyazi, O Blanck, C Baues, R Baumann, S Dobiasch, ... Strahlentherapie und Onkologie 194 (2), 79-90, 2018 | 39 | 2018 |
| Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer S Temming, M Kocher, E Stoelben, L Hagmeyer, C De-Hua, F Konrad, ... Strahlentherapie und Onkologie 194 (2), 91-97, 2018 | 38 | 2018 |
